Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
70
BBP Quote, Financials, Valuation and Earnings
Last price:
$82.62
Seasonality move
:
-1.99%
Day range:
$81.37 - $81.71
52-week range:
$48.65 - $82.63
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
2K
Avg. volume:
8.5K
1-year change:
33.29%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | -- | -- | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- |
|
PFFR
InfraCap REIT Preferred ETF
|
-- | -- | -- | -- | -- |
|
XBI
State Street SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BBP
Virtus LifeSci Biotech Products ETF
|
$81.63 | -- | -- | -- | $0.00 | 0% | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
$39.56 | -- | -- | -- | $0.66 | 1.66% | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
$83.82 | -- | -- | -- | $0.42 | 0.98% | -- |
|
PFFR
InfraCap REIT Preferred ETF
|
$18.15 | -- | -- | -- | $0.12 | 7.93% | -- |
|
XBI
State Street SPDR S&P Biotech ETF
|
$124.98 | -- | -- | -- | $0.41 | 0.36% | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
$108.62 | -- | -- | -- | $0.12 | 0.27% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | 0.818 | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | 1.813 | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | 0.859 | -- | -- |
|
PFFR
InfraCap REIT Preferred ETF
|
-- | 0.378 | -- | -- |
|
XBI
State Street SPDR S&P Biotech ETF
|
-- | 1.273 | -- | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
-- | 0.960 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | -- | -- | -- | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- | -- |
|
PFFR
InfraCap REIT Preferred ETF
|
-- | -- | -- | -- | -- | -- |
|
XBI
State Street SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- | -- |
|
XHS
State Street SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- | -- |
Virtus LifeSci Biotech Products ETF vs. Competitors
-
Which has Higher Returns BBP or BBC?
Virtus LifeSci Biotech Clinical Trials ETF has a net margin of -- compared to Virtus LifeSci Biotech Products ETF's net margin of --. Virtus LifeSci Biotech Products ETF's return on equity of -- beat Virtus LifeSci Biotech Clinical Trials ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBPVirtus LifeSci Biotech Products ETF-- -- -- BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -
What do Analysts Say About BBP or BBC?
Virtus LifeSci Biotech Products ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Virtus LifeSci Biotech Clinical Trials ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Products ETF has higher upside potential than Virtus LifeSci Biotech Clinical Trials ETF, analysts believe Virtus LifeSci Biotech Products ETF is more attractive than Virtus LifeSci Biotech Clinical Trials ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBPVirtus LifeSci Biotech Products ETF0 0 0 BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 -
Is BBP or BBC More Risky?
Virtus LifeSci Biotech Products ETF has a beta of 0.640, which suggesting that the stock is 35.974% less volatile than S&P 500. In comparison Virtus LifeSci Biotech Clinical Trials ETF has a beta of 0.983, suggesting its less volatile than the S&P 500 by 1.702%.
-
Which is a Better Dividend Stock BBP or BBC?
Virtus LifeSci Biotech Products ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Virtus LifeSci Biotech Clinical Trials ETF offers a yield of 1.66% to investors and pays a quarterly dividend of $0.66 per share. Virtus LifeSci Biotech Products ETF pays -- of its earnings as a dividend. Virtus LifeSci Biotech Clinical Trials ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBP or BBC?
Virtus LifeSci Biotech Products ETF quarterly revenues are --, which are smaller than Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues of --. Virtus LifeSci Biotech Products ETF's net income of -- is lower than Virtus LifeSci Biotech Clinical Trials ETF's net income of --. Notably, Virtus LifeSci Biotech Products ETF's price-to-earnings ratio is -- while Virtus LifeSci Biotech Clinical Trials ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Products ETF is -- versus -- for Virtus LifeSci Biotech Clinical Trials ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBPVirtus LifeSci Biotech Products ETF-- -- -- -- BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- --
-
Which has Higher Returns BBP or PBE?
Invesco Biotechnology & Genome ETF has a net margin of -- compared to Virtus LifeSci Biotech Products ETF's net margin of --. Virtus LifeSci Biotech Products ETF's return on equity of -- beat Invesco Biotechnology & Genome ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBPVirtus LifeSci Biotech Products ETF-- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- -
What do Analysts Say About BBP or PBE?
Virtus LifeSci Biotech Products ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Biotechnology & Genome ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Products ETF has higher upside potential than Invesco Biotechnology & Genome ETF, analysts believe Virtus LifeSci Biotech Products ETF is more attractive than Invesco Biotechnology & Genome ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBPVirtus LifeSci Biotech Products ETF0 0 0 PBEInvesco Biotechnology & Genome ETF0 0 0 -
Is BBP or PBE More Risky?
Virtus LifeSci Biotech Products ETF has a beta of 0.640, which suggesting that the stock is 35.974% less volatile than S&P 500. In comparison Invesco Biotechnology & Genome ETF has a beta of 0.822, suggesting its less volatile than the S&P 500 by 17.787%.
-
Which is a Better Dividend Stock BBP or PBE?
Virtus LifeSci Biotech Products ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Invesco Biotechnology & Genome ETF offers a yield of 0.98% to investors and pays a quarterly dividend of $0.42 per share. Virtus LifeSci Biotech Products ETF pays -- of its earnings as a dividend. Invesco Biotechnology & Genome ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBP or PBE?
Virtus LifeSci Biotech Products ETF quarterly revenues are --, which are smaller than Invesco Biotechnology & Genome ETF quarterly revenues of --. Virtus LifeSci Biotech Products ETF's net income of -- is lower than Invesco Biotechnology & Genome ETF's net income of --. Notably, Virtus LifeSci Biotech Products ETF's price-to-earnings ratio is -- while Invesco Biotechnology & Genome ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Products ETF is -- versus -- for Invesco Biotechnology & Genome ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBPVirtus LifeSci Biotech Products ETF-- -- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- --
-
Which has Higher Returns BBP or PFFR?
InfraCap REIT Preferred ETF has a net margin of -- compared to Virtus LifeSci Biotech Products ETF's net margin of --. Virtus LifeSci Biotech Products ETF's return on equity of -- beat InfraCap REIT Preferred ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBPVirtus LifeSci Biotech Products ETF-- -- -- PFFRInfraCap REIT Preferred ETF-- -- -- -
What do Analysts Say About BBP or PFFR?
Virtus LifeSci Biotech Products ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand InfraCap REIT Preferred ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Products ETF has higher upside potential than InfraCap REIT Preferred ETF, analysts believe Virtus LifeSci Biotech Products ETF is more attractive than InfraCap REIT Preferred ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBPVirtus LifeSci Biotech Products ETF0 0 0 PFFRInfraCap REIT Preferred ETF0 0 0 -
Is BBP or PFFR More Risky?
Virtus LifeSci Biotech Products ETF has a beta of 0.640, which suggesting that the stock is 35.974% less volatile than S&P 500. In comparison InfraCap REIT Preferred ETF has a beta of 0.717, suggesting its less volatile than the S&P 500 by 28.347%.
-
Which is a Better Dividend Stock BBP or PFFR?
Virtus LifeSci Biotech Products ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfraCap REIT Preferred ETF offers a yield of 7.93% to investors and pays a quarterly dividend of $0.12 per share. Virtus LifeSci Biotech Products ETF pays -- of its earnings as a dividend. InfraCap REIT Preferred ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBP or PFFR?
Virtus LifeSci Biotech Products ETF quarterly revenues are --, which are smaller than InfraCap REIT Preferred ETF quarterly revenues of --. Virtus LifeSci Biotech Products ETF's net income of -- is lower than InfraCap REIT Preferred ETF's net income of --. Notably, Virtus LifeSci Biotech Products ETF's price-to-earnings ratio is -- while InfraCap REIT Preferred ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Products ETF is -- versus -- for InfraCap REIT Preferred ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBPVirtus LifeSci Biotech Products ETF-- -- -- -- PFFRInfraCap REIT Preferred ETF-- -- -- --
-
Which has Higher Returns BBP or XBI?
State Street SPDR S&P Biotech ETF has a net margin of -- compared to Virtus LifeSci Biotech Products ETF's net margin of --. Virtus LifeSci Biotech Products ETF's return on equity of -- beat State Street SPDR S&P Biotech ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBPVirtus LifeSci Biotech Products ETF-- -- -- XBIState Street SPDR S&P Biotech ETF-- -- -- -
What do Analysts Say About BBP or XBI?
Virtus LifeSci Biotech Products ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand State Street SPDR S&P Biotech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Products ETF has higher upside potential than State Street SPDR S&P Biotech ETF, analysts believe Virtus LifeSci Biotech Products ETF is more attractive than State Street SPDR S&P Biotech ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBPVirtus LifeSci Biotech Products ETF0 0 0 XBIState Street SPDR S&P Biotech ETF0 0 0 -
Is BBP or XBI More Risky?
Virtus LifeSci Biotech Products ETF has a beta of 0.640, which suggesting that the stock is 35.974% less volatile than S&P 500. In comparison State Street SPDR S&P Biotech ETF has a beta of 0.931, suggesting its less volatile than the S&P 500 by 6.918%.
-
Which is a Better Dividend Stock BBP or XBI?
Virtus LifeSci Biotech Products ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. State Street SPDR S&P Biotech ETF offers a yield of 0.36% to investors and pays a quarterly dividend of $0.41 per share. Virtus LifeSci Biotech Products ETF pays -- of its earnings as a dividend. State Street SPDR S&P Biotech ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBP or XBI?
Virtus LifeSci Biotech Products ETF quarterly revenues are --, which are smaller than State Street SPDR S&P Biotech ETF quarterly revenues of --. Virtus LifeSci Biotech Products ETF's net income of -- is lower than State Street SPDR S&P Biotech ETF's net income of --. Notably, Virtus LifeSci Biotech Products ETF's price-to-earnings ratio is -- while State Street SPDR S&P Biotech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Products ETF is -- versus -- for State Street SPDR S&P Biotech ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBPVirtus LifeSci Biotech Products ETF-- -- -- -- XBIState Street SPDR S&P Biotech ETF-- -- -- --
-
Which has Higher Returns BBP or XHS?
State Street SPDR S&P Health Care Services ETF has a net margin of -- compared to Virtus LifeSci Biotech Products ETF's net margin of --. Virtus LifeSci Biotech Products ETF's return on equity of -- beat State Street SPDR S&P Health Care Services ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBPVirtus LifeSci Biotech Products ETF-- -- -- XHSState Street SPDR S&P Health Care Services ETF-- -- -- -
What do Analysts Say About BBP or XHS?
Virtus LifeSci Biotech Products ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand State Street SPDR S&P Health Care Services ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Products ETF has higher upside potential than State Street SPDR S&P Health Care Services ETF, analysts believe Virtus LifeSci Biotech Products ETF is more attractive than State Street SPDR S&P Health Care Services ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBPVirtus LifeSci Biotech Products ETF0 0 0 XHSState Street SPDR S&P Health Care Services ETF0 0 0 -
Is BBP or XHS More Risky?
Virtus LifeSci Biotech Products ETF has a beta of 0.640, which suggesting that the stock is 35.974% less volatile than S&P 500. In comparison State Street SPDR S&P Health Care Services ETF has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.625%.
-
Which is a Better Dividend Stock BBP or XHS?
Virtus LifeSci Biotech Products ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. State Street SPDR S&P Health Care Services ETF offers a yield of 0.27% to investors and pays a quarterly dividend of $0.12 per share. Virtus LifeSci Biotech Products ETF pays -- of its earnings as a dividend. State Street SPDR S&P Health Care Services ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBP or XHS?
Virtus LifeSci Biotech Products ETF quarterly revenues are --, which are smaller than State Street SPDR S&P Health Care Services ETF quarterly revenues of --. Virtus LifeSci Biotech Products ETF's net income of -- is lower than State Street SPDR S&P Health Care Services ETF's net income of --. Notably, Virtus LifeSci Biotech Products ETF's price-to-earnings ratio is -- while State Street SPDR S&P Health Care Services ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Products ETF is -- versus -- for State Street SPDR S&P Health Care Services ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBPVirtus LifeSci Biotech Products ETF-- -- -- -- XHSState Street SPDR S&P Health Care Services ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
